Conventional Papanicolaou smear method is still commonly used for cervical cancer screening in Japan, despite the liquid-based cytology (LBC) that has become a global tendency in the world recently. One of the obstacles in the way of popularization of this method seems to be the confusion as to diagnosis upon cervical glandular lesions. We performed comparison study between LBC and conventional Papanicolaou smear about cytological diagnosis using split-sample method in 4522 patients. In 13 cases analyses, which were reported with either AGC or adenocarcinoma by either method, LBC tends to be milder than that by conventional smear, however, the credibility of LBC is considered to be near to that of conventional smear with regard to screening for glandular abnormalities. These results indicate that cervical cancer screening should shift to LBC under the enough experience and appropriate dealing with the cytological diagnosis. 1. Introduction Uterine cervical cancer is still the most commonly diagnosed cancer among women worldwide, taking second place only after breast cancer [1–4]. The incidence and mortality from cervical cancer decreased considerably in most industrial countries due to lower incidence and the introduction of screening [5, 6]. On the other hand, malignant or precancerous lesions of glandular cells in uterine cervix are increasing recently, as reported that the incidence of adenocarcinoma of Japan is 16.8% in 2009, and many studies reported higher mortality rate of cervical adenocarcinoma [7–12]. The screenings of the glandular lesions are thought to be difficult in comparison with those of the squamous epithelium type, although those early diagnoses become more important for prognosis improvement. In late years, Japan Association of Obstetricians and Gynecologists announced a standardized system of terminology reflected by the Bethesda system (TBS) and the screening of cervical lesions are being performed based on this system [13]. In this new Japanese system, increasing numbers of facilities come to use LBC, which is a global tendency, despite the premise to use conventional smears for sampling. In many reports of the comparison studies between LBC and conventional smear with clinical and histological followups, LBC is better than conventional smear in detecting biopsy-proven disease and in screening out benign abnormalities in terms of squamous lesions [14–22]. However, it still remains unclear how to evaluate the cytological diagnosis of the glandular lesion in the new system using LBC. We recently started TBS application using both
References
[1]
D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.
[2]
A. Figo, “Cervical cancer prevention in low-resource settings,” International Journal of Gynecology and Obstetrics, vol. 90, no. 1, pp. 86–87, 2005.
[3]
M. A. Quinn, J. L. Benedet, F. Odicino, et al., “Carcinoma of the cervix uteri. FIGO 6th Annual Report on the results of treatment in gynecological cancer,” International Journal of Gynecology & Obstetrics, vol. 95, supplement 1, pp. 43–103, 2006.
[4]
R. Sankaranarayanan, “Overview of cervical cancer in the developing world. FIGO 6th Annual Report on the results of treatment in gynecological cancer,” International Journal of Gynecology & Obstetrics, vol. 95, supplement 1, pp. 205–210, 2006.
[5]
M. Arbyn, A. O. Raifu, E. Weiderpass, F. Bray, and A. Anttila, “Trends of cervical cancer mortality in the member states of the European Union,” European Journal of Cancer, vol. 45, no. 15, pp. 2640–2648, 2009.
[6]
American Cancer Society, Cancer Facts & Figures 2010, American Cancer Society, 2010.
[7]
S. Liu, R. Semenciw, A. Probert, and Y. Mao, “Cervical cancer in Canada: changing patterns in incidence and mortality,” International Journal of Gynecological Cancer, vol. 11, no. 1, pp. 24–31, 2001.
[8]
B. E. Miller, S. D. Flax, K. Arheart, and G. Photopulos, “The presentation of adenocarcinoma of the uterine cervix,” Cancer, vol. 72, no. 4, pp. 1281–1285, 1993.
[9]
R. K. Peters, A. Chao, and T. M. Mack, “Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County,” Journal of the National Cancer Institute, vol. 76, no. 3, pp. 423–428, 1986.
[10]
S. M. Schwartz and N. S. Weiss, “Increased incidence of adenocarcinoma of the cervix in young women in the United States,” American Journal of Epidemiology, vol. 124, no. 6, pp. 1045–1047, 1986.
[11]
H. O. Smith, M. F. Tiffany, C. R. Qualls, and C. R. Key, “The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study,” Gynecologic Oncology, vol. 78, no. 2, pp. 97–105, 2000.
[12]
Japanese Society of Obstetrics and Gynecology, “Patient Annual Report 2009,” Acta Obstetricia et Gynecologica, vol. 63, no. 3, pp. 1055–1099, 2011.
[13]
Japanese Society of Obstetrics and Gynecology, “The guideline of cytological reporting based on the Bethesda System 2001,” 2008.
[14]
A. K. Adhya, V. Mahesha, R. Srinivasan et al., “Atypical glandular cells in cervical smears: histological correlation and a suggested plan of management based on age of the patient in a low-resource setting,” Cytopathology, vol. 20, no. 6, pp. 375–379, 2009.
[15]
N. I. Mood, Z. Eftekhar, A. Haratian, L. Saeedi, P. Rahimi-Moghaddam, and F. Yarandi, “A cytohistologic study of atypical glandular cells detected in cervical smears during cervical screening tests in Iran,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 257–261, 2006.
[16]
H. S. Mitchell, “Outcome after a cytological prediction of glandular abnormality,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 44, no. 5, pp. 436–440, 2004.
[17]
P. J. J. M. Klinkhamer, W. J. Meerding, P. F. W. M. Rosier, and A. G. J. M. Hanselaar, “Liquid-based cervical cytology: a review of the literature with methods of evidence-based medicine,” Cancer, vol. 99, no. 5, pp. 263–271, 2003.
[18]
J. S. Bentz, L. R. Rowe, E. V. Gopez, and C. J. Marshall, “The unsatisfactory ThinPrep Pap Test missed opportunity for disease detection?” American Journal of Clinical Pathology, vol. 117, no. 3, pp. 457–463, 2002.
[19]
L. Minge, M. Fleming, T. VanGeem, and J. W. Bishop, “AutoCyte Prep system vs. conventional cervical cytology: comparison based on 2,156 cases,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 45, no. 3, pp. 179–184, 2000.
[20]
M. L. Hutchinson, D. J. Zahniser, M. E. Sherman et al., “Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma,” Cancer, vol. 87, no. 2, pp. 48–55, 1999.
[21]
A. B. Carpenter and D. D. Davey, “ThinPrep Pap test: performance and biopsy follow-up in a University Hospital,” Cancer, vol. 87, no. 3, pp. 105–112, 1999.
[22]
K. R. Lee, R. Ashfaq, G. G. Birdsong, M. E. Corkill, K. M. McIntosh, and S. L. Inhorn, “Comparison of conventional Papanicolaou smears and a fluid-based, thin- layer system for cervical cancer screening,” Obstetrics and Gynecology, vol. 90, no. 2, pp. 278–284, 1997.
[23]
M. Nishiwaki, T. Yamamoto, S. Tone et al., “Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications,” Journal of Clinical Microbiology, vol. 46, no. 4, pp. 1161–1168, 2008.
[24]
A. J. M. van Aspert-van Erp, F. M. M. Smedts, and G. P. Vooijs, “Severe cervical glandular cell lesions and severe cervical combined lesions: predictive value of the Papanicolaou smear,” Cancer, vol. 102, no. 4, pp. 210–217, 2004.